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Public–private health partnerships: a strategy
for WHO
Kent Buse1 & Amalia Waxman2
Abstract Following early success with a number of high-profile partnerships, WHO is increasingly working with
the private for-profit sector. In so doing, the organization finds itself in the maelstrom of a vibrant debate on the
roles of public, civic, and commercial entities in society and on the appropriate modes of interaction among them.
This paper examines WHO’s involvement with the commercial sector, particularly in partnerships. WHO’s approach
to this sector is outlined and the criticisms levelled at public–private partnerships are reviewed. An indication is
given of the steps recently taken by WHO to confront the concerns that have been expressed. The paper argues that
partnership between WHO and the commercial sector is inevitable and that it presents considerable opportunities,
but also significant risks, for the organization and for public health. A strategy is proposed for directing the debate
on issues critical to WHO and its role in the promotion and protection of public health.
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Introduction
In 1993 the World Health Assembly called on WHO
to mobilize and encourage the support of all partners
in health development, including nongovernmental
organizations and institutions in the private sector, in
the implementation of national strategies for health
for all (1). Subsequently, interaction with the
commercial sector has broadened and deepened.
WHO’s Director-General has stated that it was
necessary to be more innovative in creating influen-
tial partnerships and that progress was being made in
building partnerships with nongovernmental organi-
zations and the private sector (2). Partnering is
outlined in WHO’s corporate strategy as a core
function that can help to bring about health for all (3).
WHO participates in a number of global
public–private partnerships. These collaborative
relationships transcend national boundaries and
bring together at least two parties, a corporation (or
industry association) and an intergovernmental
organization, in order to achieve a health-creating
goal on the basis of a mutually agreed and explicitly
defined division of labour (4). The emergence of
these partnerships can be traced to various factors
that have been indicated elsewhere (4). The Initiative
on Public-Private Partnerships for Health has
identified nearly 70 global health partnerships (5).
This relatively new trend in global health cooperation
is demonstrating significant possibilities for tackling
problems that formerly seemed intractable, particu-
larly those requiring increased research and develop-
ment (R&D) on drugs and vaccines for diseases
disproportionately affecting the poor. For example,
several partnerships are achieving positive results
against infectious diseases: the Mectizan Donation
Programme (6), the Global Polio Eradication
Initiative, and the Global Programme to Eliminate
Lymphatic Filariasis (7). Partnerships with the private
sector have also demonstrated an ability to advance
public health messages and create industry incentives
for the development of healthier products (8).
Through collaboration, the United Nations (UN)
has the opportunity to gain access to resources and
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expertise so as to further its mission, while the
commercial sector may, through an improved
corporate image, among other things, attract new
investors and establish new markets. Many benefits,
therefore, including the immediate health-related
ones, favour the continued development of public–
private collaboration for health.
WHO and the commercial sector
WHO is inevitably engaged in various types of
interaction with the private sector, many of them
desirable and necessary. The tobacco industry, for
example, participated in public hearings organized by
WHO in October 2000 on the Framework Conven-
tion on Tobacco Control and its experts contribute
regularly to theWHOScientific Advisory Committee
on Tobacco Product Regulation. WHO’s interac-
tions with the private sector range fromworking with
employees of companies who act in their personal
expert capacities or are seconded from companies to
participate in decision-making bodies, to engaging in
more formal partnership arrangements (i.e. based on
bilateral legal agreements). This paper is principally
concerned with formal, longer-term, task-oriented
partnerships. A useful distinction has been made
between partnerships in which the management
functions are undertaken by a secretariat within an
intergovernmental agency (e.g. the Global Alliance
for Vaccines and Immunization) or in a not-for-profit
host (e.g. the Mectizan Donation Programme) and
those where the management is housed in a separate
legal entity (e.g. the International AIDS Vaccine
Initiative) (5). A more comprehensive review of
WHO’s relations with the private sector should be
aware of the spectrum of relationships as well as the
diversity embraced by the term ‘partnership’.
WHO’s enthusiasm for partnership is in line
with the UN’s ‘‘global compact’’, which aims to
promote, among other things, corporate responsi-
bility in the areas of labour, human rights, and the
environment in response to the unfavourable effects
of globalization (9). Nevertheless, WHO’s approach
to partnerships with the private sector is distinctive
because of the explicit focus on health and the ethical
principles that support its mission and values. WHO
enters into partnerships that usually seek to achieve
well-defined and specific health outcomes, such as
those that are linked to disease or risk factors. The
aims which WHO seeks to achieve through such
partnerships are listed in Box 1.
Processes governing WHO’s inter-
action with the commercial sector
The intensity, extent, and velocity of interactions
between WHO and the commercial sector over the
past decade have been unprecedented. For this
reason WHO has initiated two approaches to
regularize its processes of work with the private
sector. The first facilitates the outreach of the
organization to private partners. The second seeks
to deal with the challenges that arise from such
collaboration.
Facilitating outreach
Among the facilitating mechanisms was the designa-
tion in 1999 of a focal point for the coordination of
interactions with commercial donors. More recently,
an informal working group on private sector
engagement was formed with the purpose of sharing
information and knowledge. Some of the eight
‘‘clusters’’ of technical programmes at WHO head-
quarters have designated their own focal points for
coordinating relationships with commercial entities,
enhancing resource mobilization activities, and
seeking partnership opportunities. A gradual delega-
tion of authority to the clusters is taking place,
enabling them towork independently with the private
sector in the context of an evolving framework of
organizational rules.
A further type of outreach involves high-level
interaction with industry. In 1998, for example, a
round table process was established with chief
executive officers of the pharmaceutical industry,
the International Federation of Pharmaceutical
Manufacturers Associations, and the World Self-
Medication Industry (11). The meetings are aimed at
building trust with these bodies, raising differences
and identifying prospective partnerships. Other
examples of outreach include the Director-General’s
address to the World Economic Forum in Davos,
Switzerland, in January 2001 (12, 13).
Developing safeguards
In parallel with facilitating outreach, a process was
initiated for developing institutional safeguards that
would counterbalance potential risks and for exam-
ining concerns about global public–private partner-
ships. An internal working group met in 1996 to
consider partnership in the context of the renewal of
health for all (14). In 1999, draft guidelines on
working with the private sector were released for
comment by Member States, nongovernmental
Box 1. WHO’s aims in establishing partnerships
Through partnership, WHO seeks to:
. encourage industry to abide by the health-for-all
principles (10);
. facilitate universal access to essential drugs and health
services;
. accelerate R&D in the fields of vaccines, diagnostics, and
drugs for neglected diseases;
. prevent premature mortality, morbidity, and disability by
giving special attention to policies and behavioural
change;
. encourage industry to develop products in ways that are
less harmful to workers and the environment;
. acquire knowledge and expertise from the commercial
sector;
. enhance WHO’s image among typically hostile constitu-
encies.
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organizations, and academia (15). Their objective was
to help staff to interact appropriately with commer-
cial enterprises in order to achieve positive outcomes
for health. The document included procedures
concerning the implementation of the guidelines.
An internal Committee on Private Sector Collabora-
tion was established in 1999 to review the suitability
and compatibility of proposals for partnership with
organizational policies and guidelines.
In 2000 a document aimed atWHO experts was
issued with the goal of ensuring that the best possible
assessment of scientific evidence was achieved in an
atmosphere free of either direct or indirect pressure
(16). It asks experts to disclose informationon financial
and other interests with commercial entities. In an
attempt to address the issues involved more fully, a
briefing paper on conflict of interest was recently
commissioned by the organization. Furthermore, a
mechanism was devised to screen the suitability of
candidate firms for partnerships with WHO (17). It
provides a systematic way for assessing companies in
accordance with criteria relating to human rights,
labour and environmental standards, product char-
acteristics, involvement in the manufacturing of
dangerous products, and so on.
As WHO introduces mechanisms intended to
safeguard its integrity, it finds itself at the centre of
debate on the appropriateness of public–private
collaboration. On the one hand, a ground swell of
support for partnerships is evident. Practitioners
wish to avail themselves of promising opportunities
and to initiate new partnerships in order to meet
urgent needs. These proponents are often frustrated
by the perceived slowness with whichWHO acts and
view its guidelines and procedures as a hindrance to
their efforts. On the other hand, at a recent meeting
of the WHO Executive Board a significant number
of members drew attention to a variety of actual or
potential perils associated with public–private part-
nership. The suggestion has been made that precau-
tions established by the organization are inadequate
(18, 19).
A critique of partnerships
Public–private collaboration has elicited strenuous
objections. The types of questions that have arisen
include: are partnerships desirable, and under what
circumstances, from a societal point of view? What
are the appropriate criteria for the selection of
candidate companies, industries and activities, and
how are such criteria developed? How can interac-
tions be structured and monitored in order to avoid
or deal with conflicts of interest? How can partner-
ships be made to function in accordance with
principles of good governance?
A slippery slope
Some critics situate public–private partnerships within
a discourse over the appropriate role of the state and
public institutions in society. In relation to the UN,
fears arise that inadequately monitored relations with
the commercial sector may subordinate the values and
reorient the mission of its organs, detract from their
abilities to establish norms and standards free of
commercial considerations, weaken their capacity to
promote and monitor international regulations, dis-
place organizational priorities, and induce self-censor-
ship, among other things. Interaction, it is argued, may
result in these outcomes, not just because the sectors
pursue opposing underlying interests, but because the
UN, having very limited resources, may face institu-
tional capture by its more powerful partners. Critics
argue that new partnerships are leading down a
slippery slope towards the partial privatization and
commercialization of the UN system (20). Partner-
ships, it is asserted, are the thin edge of a wedge
whereby international public authority, as exercised
through the UN, gives way to a norm of voluntary
private regulation in which the UN simply provides
endorsement and legitimization (21).
Shifting responsibilities
Other critics have argued that partnership enables
nation states to abdicate their responsibilities for the
promotion and protection of their citizens’ health.
These critics contend that partnerships may legiti-
mize the withdrawal of social safety nets, resulting in
the benefits of partnership being restricted to islands
of excellence in seas of underprovision, while
seemingly exonerating public authorities from blame
for breaching the social contract (22).
A danger for WHO
In relation toWHO, critics believe that some of their
fears are materializing. For example, it is charged that
the independent setting of standards was jeopardized
during the elaboration of the guidelines for the
management of hypertension because of the influ-
ence of a firm that stood to benefit from them (23).
Similarly, it has been asserted that deliberations on
breastfeeding were subject to ‘‘censorship’’ because
of considerations of the sensibilities of WHO’s new
commercial constituencies (24). Others argue that
WHO’s emphasis on the marginalized will be
displaced as resource-rich partnerships dictate orga-
nizational priorities and strategies. It has been
suggested that WHO’s involvement in the Global
Alliance for Vaccines and Immunization has derailed
its commitment to equity in relation to the goal of
universal vaccination with traditional vaccines, as it
joins its partners in bringing new vaccines to the
relatively less hard to reach (25). Moreover, for
understandable reasons, partnerships sometimes
focus, at least initially, on countries and activities
that offer a reasonable chance of success. Thus they
usually concentrate on relatively affluent countries
rather than on those that are very poor, and on drug
donations and development instead of the more
difficult challenges of capacity development for
service delivery and research in low-income countries
(26). Yet even relatively non-controversial initiatives,
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such as donation programmes, may have consider-
able and unintended consequences linked, for
example, with costs to recipients, sustainability, and
equity, which could damage WHO’s reputation by
association (27, 28).
Greater regulation
Others argue that some concerns could be eased if
relations with the commercial sector were better
regulated and if WHO entered only into partnerships
that were reasonably well governed (29). Institutional
procedures for ensuring adequate representation are
evidently underdeveloped and most partnerships in
which WHO participates therefore have little
representation on their governing bodies from low-
income and middle-income countries (26). There is
little information in the public domain regarding the
composition of oversight bodies; the volume,
allocation and monitoring of resources; how deci-
sions are made; and who can be held responsible for
them. In order that partnerships inspire confidence
and assuage the concerns of the sceptics, their
governing arrangements should be improved and
made more transparent.
The future
Although there have been some success stories, it is
too early to predict the consequences of partnership.
Many partnerships are new and best seen as social
experiments. Despite their novelty and the concerns
they provoke, partnerships have not been subjected
to significant empirical research. Some observers
have called for a moratorium on partnerships until
more reflection is possible (30). An alternative
approach, although somewhat bureaucratic, is a
precautionary one. In WHO, such caution has
manifest itself in the form of guidelines and internal
monitoring arrangements. These precautions have
been welcomed by some critics but many view them
as inadequate both in substance and process (19, 31).
Addressing the critique: developing a
strategy for WHO
In response to mounting concerns over WHO
involvement with the commercial sector, the Direc-
tor-General gave an assurance that funds would not
be accepted if the conditions on which they were
provided went against the organization’s values or
undermined its governance structures and estab-
lished procedures (32). What is needed is an
operational strategy that enables WHO to enter into
public–private partnerships while safeguarding its
values and improving the accountability and trans-
parency of its operations. Such a strategy will have to
provide sufficient flexibility to differentiate the types
of risk to the organization: a single approach for all
circumstances is unlikely to be useful. The strategy
should also encourage staff to become involved in
partnering work and guard against excessive institu-
tionalization. One option would be to leave the
question of the suitability of partnership activities to
the discretion of WHOmanagers, guided by existing
rules and procedures. This, however, would fail to
placate critics who argue that the present arrange-
ments are not adequate for balancing benefits against
potential risks. Another option would involve further
action to tackle the critique. The proposals that
follow are intended to stimulate debate on specific
areas that may require such action. Details of more
specificmeasures and a consideration of their costs to
WHO can be obtained from the authors.
Organizational policy
There should be a statement that clarifies WHO’s
approach to partnership in the context of itsmandate.
This statement should reconcile and align commer-
cial partnerships with WHO’s commitment to a
number of non-negotiable, health-for-all principles
(10). It is necessary to specify what the organization
wishes to achieve from partnership, how to use
partnerships so that its technical expertise and moral
authority can achieve greater health gains, how to
address the many potential problems inherent in
partnership, and when and why to reject partnership.
The development of such a policy would require
broad consultation, both internal and external.
Guidelines
Each proposed partnership should be reviewed in
terms of its alignment and compliance with WHO’s
mission, priorities, policies, and procedures. The
Committee on Private Sector Collaboration currently
holds this responsibility but relies on inadequately
articulated policy and circumscribed guidelines which
fail to place the procedures relating to individual
initiatives within a framework of the organization’s
mission and priorities. Although detailed guidance is
given on a number of activities, e.g. stipulations are
made in respect of donations and seconded person-
nel, they lack clarity on conflicts of interest, the
appropriateness of interacting with individual indus-
tries, companies and activities, dealing with multi-
party collaboration, institutional arrangements
governing partnerships, and other issues. The
development of a broad-based policy could lead to
improvements in the operational guidelines on
engagement with industry. External inputs into both
the guidelines and procedures throughwhich they are
to be implemented should be considered.
Selection of partner companies
The present approach to the selection of partner
companies, which relies on in-house assessments,
seems inappropriate. Our perception is that WHO
does not seem to have the expertise or capacity
needed for screening companies in a credible
manner. We believe an effort should be made to
contract this work to a suitable third party, e.g. a
professional audit service, a civil society organization,
or a specially mandated UN body.
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Governance
While it is acknowledged that each partnership has
unique needs in relation to its governance arrange-
ments and that excessive institutionalization may
detract from the positive attributes of partnerships
such as innovation and flexibility, there are convin-
cing arguments in favour of establishing benchmarks
of good practice. Although evidence about good
practice remains scarce, we believe that partnerships
involving WHO should meet the requirements
outlined in Box 2.
Mechanisms to ensure WHO’s accountability
Real and perceived conflicts of interest suggest that it
may be worth subjecting WHO’s involvement with
the commercial sector to greater external scrutiny.
Improved oversight could, in part, be accomplished
by placing more information in the public domain.
For example, minutes relating to decisions of the
Committee on Private Sector Collaboration as well as
partnership agreements could be posted on the
Internet and the establishment of a ‘‘partnership
ombudsperson’’ could be considered as a means of
improving communication and transparency. In
addition to consultation with public agencies,
enhanced efforts could be made to obtain inputs
from civil society.
Leadership on partnering knowledge
WHOshould promote and support research aimed at
identifying good partnership practice and leveraging
private sector contributions to health development.
The organization should draw lessons from its own
experience of partnership and develop indicators of
success. Comparative research is required to under-
stand the impact of differing institutional arrange-
ments on effectiveness and efficiency, optimal
approaches to managing intellectual property, hand-
ling confidentiality, and good practice relating to
raising social capital, etc. Furthermore, it is desirable
to understand better how to achieve appropriate
oversight of multiparty partnerships in which WHO
plays a minor role or none at all. Other groups are
undertaking such work, but a more proactive
engagement of WHO in this area of research could
prove extremely valuable.
Conclusions
Public–private partnerships are a central feature of
the global health landscape and there seems no
reason to believe that the current trend will not
continue (33). WHO should not shy away from
partnership or interaction with the commercial
sector. Although the evidence is still limited, there
are grounds for believing that many initiatives may
meet various needs in public health. Partnerships,
however, clearly require improved systems of
institutional governance. Systems should be estab-
lished within public sector agencies to ensure that the
greatest possible importance is attached to protecting
the public’s interest. WHO should be proactive and
enter into partnerships on the basis of a comprehen-
sive and broadly agreed strategy so as to allay the
concerns of critics and proponents alike. By adhering
to widely endorsed guidelines on interaction with the
commercial sector, WHO can not only protect its
integrity and legitimacy but can also confer its
valuable imprimatur on deserving partnerships. n
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Box 2. Governance requirements
Partnerships involving WHO should:
. be governed by bodies that are widely representative yet
give WHO adequate decision-making power so as to
reflect its position as the premier health organization with
universal representation. Moreover, the governing bodies
should have mechanisms ensuring the participation of
constituencies that might otherwise lack the material
resources needed in order to participate, particularly
those that provide a counterbalance to the influence of
industry. All members should undertake to adhere to
WHO principles.
. establish clear goals, roles, responsibilities, and decision-
making structures, and the means of monitoring and
enforcing decisions should be taken into consideration.
. establish systems of communication whereby information
about decision-making structures, funding, resource
allocation and results is regularly conveyed to all
concerned, and should provide for consultation with
stakeholders.
. document and publicize details of the process and
outcomes of the partnership.
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Re´sume´
Partenariats public-prive´ pour la sante´ : une strate´gie pour l’OMS
Compte tenu des bons re´sultats rapidement obtenus
dans le cadre d’un certain nombre de partenariats en
vue, l’OMS collabore de plus en plus avec le secteur prive´
a` but lucratif. Ce faisant, l’Organisation se place au cœur
d’un de´bat passionne´ sur les roˆles respectifs des entite´s
publiques, politiques et commerciales dans la socie´te´ et
sur les modes approprie´s d’interaction entre elles. Le
pre´sent article porte sur les rapports de l’OMS avec le
secteur commercial, notamment dans le cadre de
partenariats. La ligne d’action de l’Organisation y est
expose´e dans ses grandes lignes et les critiques
formule´es a` l’encontre des partenariats public-prive´ y
sont examine´es. Les mesures prises re´cemment par
l’OMS pour re´pondre aux questions qui se posent sont
e´galement e´voque´es. Le pre´sent article fait valoir que le
partenariat entre l’OMS et le secteur commercial est
ine´vitable et que s’il offre des avantages conside´rables il
pre´sente aussi des risques importants tant pour
l’Organisation que pour la sante´ publique. Une strate´gie
est propose´e pour orienter le de´bat sur des questions
essentielles pour l’OMS quant a` son roˆle dans la
promotion et la protection de la sante´ publique.
Resumen
Alianzas de los sectores pu´blico y privado en pro de la salud: una estrategia para la OMS
En la lı´nea de los primeros e´xitos cosechados con varias
alianzas muy destacadas, la OMS esta´ colaborando cada
vez ma´s con el sector privado de fines lucrativos. La
Organizacio´n se ha encontrado ası´ en la vora´gine de un
acalorado debate acerca de los papeles de las entidades
pu´blicas, civiles y comerciales en la sociedad y de las
formas apropiadas de interaccio´n entre ellas. En este
artı´culo se examina la participacio´n de la OMS en el
sector comercial, en particular en diversas alianzas. Se
resume brevemente el enfoque aplicado por la OMS en
este sector, y se analizan las crı´ticas dirigidas contra las
alianzas de los sectores pu´blico y privado. Se indican
asimismo las medidas adoptadas recientemente por la
OMS para atender las preocupaciones expresadas. En el
artı´culo se sostiene que la colaboracio´n entre la OMS y el
sector comercial es inevitable y brinda numerosas
oportunidades, aunque tambie´n entran˜a riesgos impor-
tantes, tanto para la Organizacio´n como para la salud
pu´blica. Se propone una estrategia para orientar el
debate sobre aspectos de crucial importancia para la
OMS y sobre el papel de e´sta en la promocio´n y
proteccio´n de la salud pu´blica
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